Sarcoma, EwingBIOVESNCT07685405
Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas
An observational study of Sarcoma, Ewing, run by Istituto Ortopedico Rizzoli at 1 site in Italy.
Trial summary
The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Sarcoma, Ewing
- What is being tested?
- one blood sample and 3 blood samples
- How many people
- 16 participants
- Where
- 1 siteItaly
- Study dates
- 15 Apr 2026to Apr 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: The study aims to enroll patients of any gender who are being treated at the Rizzoli Orthopedic Institute in the following departments: Orthopedic and Traumatology Clinic III (with a primary focus on oncology), General and Thoracic Surgery (for both cancer and non-cancer patients), and Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies (for cancer patients only).
Who may be able to join
- Male and female patients of any age diagnosed with Ewing sarcoma.
- Signed, study-specific informed consent form for the BIOVES study (cancer patients)
- Male and female patients of legal age without a cancer diagnosis.
- Signed, study-specific informed consent form for the BIOVES study (non-cancer patients)
Who cannot join
- Patients who do not meet all inclusion criteria
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle
Bologna, BO, 40136
Katia Scotlandi, MSc, 390516366760, katia.scotlandi@ior.it
About this study
Official title: Feasibility Study for the Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas
The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches
- Conditions
- Sarcoma, Ewing
- Being tested
- one blood sample, 3 blood samples
- Medical subject headings
- Sarcoma, Ewing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
one blood sampleOther
non onco
3 blood samplesOther
onco
| Study group | Role | What they receive |
|---|---|---|
| oncological subject | Not described Receives: Other: 3 blood samples | |
| non-oncological subjects | Not described Receives: Other: one blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
characterisation of circulating biomarkers
search for circulating biomarkers from blood samples taken at three different time points
Measured: at baseline (time 0); before surgery; after 6 months from surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start15 Apr 2026
- Primary completionApr 2028 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcoma, EwingStudies of the same condition, open and under way.
- More trials run by Istituto Ortopedico RizzoliThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituto Ortopedico Rizzoli
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07685405
- Sponsor's protocol ID
- BIOVES
- Acronym
- BIOVES
- Status last verified
- Jun 2026
- First submitted
- 29 Jun 2026
- Last updated
- 6 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study for the Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas
- ClinicalTrials.gov ID
- NCT07685405
- Acronym / sponsor ID
- BIOVES / BIOVES
- Conditions
- Sarcoma, Ewing
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- Istituto Ortopedico RizzoliUniversity, hospital or other
- Study start
- 15 Apr 2026 (actual)
- Primary completion
- Apr 2028 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| oncological subject | – | Other: 3 blood samples |
| non-oncological subjects | – | Other: one blood sample |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- The study aims to enroll patients of any gender who are being treated at the Rizzoli Orthopedic Institute in the following departments: Orthopedic and Traumatology Clinic III (with a primary focus on oncology), General and Thoracic Surgery (for both cancer and non-cancer patients), and Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies (for cancer patients only).
Key inclusion criteria (4 listed)
- Male and female patients of any age diagnosed with Ewing sarcoma.
- Signed, study-specific informed consent form for the BIOVES study (cancer patients)
- Male and female patients of legal age without a cancer diagnosis.
- Signed, study-specific informed consent form for the BIOVES study (non-cancer patients)
Key exclusion criteria (2 listed)
- Patients who do not meet all inclusion criteria
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| one blood samplenon onco | Other | non-oncological subjects |
| 3 blood samplesonco | Other | oncological subject |
Primary outcome
characterisation of circulating biomarkers
Time frame: at baseline (time 0); before surgery; after 6 months from surgery
search for circulating biomarkers from blood samples taken at three different time points
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Sarcoma, Ewing
RecruitingPhase 1/2
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
Not yet recruitingPhase 1
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Neuroblastoma (NBL), Ewing Sarcoma
Not yet recruitingPhase 1/2
Combination Immunotherapy Targeting Sarcomas
Sarcoma, Osteoid Sarcoma
RecruitingPhase 1
International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma
High-risk GD2 Positive Ewing Sarkoma
Not yet recruitingPhase 1/2
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Sarcoma, Osteoid Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcoma, Ewing, run by Istituto Ortopedico Rizzoli at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Katia Scotlandi, MSc (39 051 6366760, katia.scotlandi@ior.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
characterisation of circulating biomarkers (time frame: at baseline (time 0); before surgery; after 6 months from surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.